After federal regulators threatened to revoke Theranos’ license to perform blood tests and ban its CEO and COO from the industry altogether, the company reportedly issued tens of thousands of corrections to blood tests it performed. Theranos has also voided all of the 2014 and 2015 results reported from its once-famed Edison blood testing machines, according to the Wall Street Journal.

The Edison machines, which were said to be able to perform more than 200 medical tests with just a few drops of blood, were key to the young biotech company earning a whopping $9 billion valuation in 2014. Yet, in the wake of reports that the machines were inaccurate and unreliable and that employees were unqualified and failing to follow proper protocols and fix problems, the company acknowledged that it had completely stopped using the devices in June 2015. Instead, the company performed its blood tests—890,000 blood tests a year, according to records—on standard lab equipment.

The corrections and voided results mean that clinics and doctor’s offices are receiving stacks of notifications. One such doctor’s office, a family practitioner in a suburb of Phoenix, told the WSJ that it received 20 corrected reports a few weeks ago. One of those corrected reports was for a patient who the doctor had sent straight to the emergency room upon receiving her Theranos results in late 2014. The corrected report shows the patient had normal results.

The unprecedented number of corrected lab results are just one of the steps Theranos is taking to try to appease the Centers for Medicare and Medicaid Services, which in March threatened to revoke the company’s license and ban CEO and founder Elizabeth Holmes, and its president and COO, Sunny Balwani, from blood testing.

Theranos has since hired new clinical laboratory advisors and it was announced last week that Balwani is leaving the company. Meanwhile, Holmes has publicly stated that she is “devastated” by the events but is taking full responsibility and will rectify the problems at the beleaguered company.

In addition to possible sanctions from the CMS, Theranos is also under criminal investigation from the Securities and Exchange Commission and the US attorney in San Francisco for allegedly misleading investors and regulators about the performance of its Edison devices.

Nevertheless, Theranos is preparing to open a new lab in Harrisburg, Pennsylvania—equipped with standard blood testing machines.